Alcimed, an innovation and new business consulting firm, highlights the importance of dealing with antimicrobial resistance and discusses the potential strategies tackling the problem.

Space exploration and brain exploration, two fields that seem very distant on paper, actually have a lot in common and can each learn from the other for the future. Alcimed, whose mission is to explore and develop uncharted territories, had the pleasure of addressing this exciting subject at a conference at the end of 2018.

The field of neuroscience has been the stage of enormous scientific and technological progress with significant investments from both public and private actors provided to increase our understanding of the functioning of human brain in physiological and pathological conditions.

In a world marked by the growth of Industry 4.0, advanced digital technologies are now emerging in drug production chains and will become competitive and operational requirements to meet tomorrow’s health challenges.

The launch and use of new drugs has traditionally been at the core of pharmaceutical companies’ marketing efforts, as the first years of commercialization provide the opportunity to take advantage of the exclusivity associated with the drug’s patent.

The government’s “My Health 2022” strategy places the improvement of the organization of care, particularly in chronic diseases, as well as the digitalization of the health system at the top of its priorities. Alcimed explored the relevance of digital solutions for the organization of care as well as the perspectives offered to healthcare stakeholders.

Avec un nombre en perpétuelle croissance de nouveaux traitements sur le marché, de régulières avancées technologiques et une multiplicité d’informations disponibles,  le domaine de l’oncologie évolue à grande vitesse et modifie le parcours diagnostic-soin-observance des patients atteints de cancer.
Chez Alcimed, nous nous sommes demandés dans quelle mesure l’oncologie serait un catalyseur d’innovations dans les années à venir.

Preclinical testing is perceived as an unavoidable and problematic step in drug development, with the major disadvantage of provoking ethical controversies related to animal welfare, while not always guaranteeing relevant results for manufacturers. Although it has long seemed unavoidable, the new organ modeling technology, “Organ-on-a-chip”, now seems to be on the way to bringing about innovation to this key stage.

After several years of listening to all stakeholders in the Unmanned Aerial Vehicle (UAV) market, and a dialogue with European and American national civil aviation agencies, the European Union Aviation Safety Agency (EASA) has finally published European regulations to provide a harmonized framework for UAV operators and manufacturers in Europe.

Ultra-resistant or super-adhesive materials, survival at great depths or adaptation to amphibious life, with 3.6 billion years of R&D, the world of nature has proven that its ability to develop cutting-edge technologies. These feats, which are by their very essence respectful of their environment, have always been a source of inspiration for manufacturers. That innovative […]